CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 5.38 HKD -2.54% Market Closed
Market Cap: 7.9B HKD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CStone Pharmaceuticals stock under the Base Case scenario is 3.56 HKD. Compared to the current market price of 5.38 HKD, CStone Pharmaceuticals is Overvalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3.56 HKD
Overvaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

33.2
P/S
P/S
Price to Sales
33.2
vs History
6
vs Industry
46
Median 3Y
6.8
Median 5Y
9
Industry
7.5
Forward
26.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-5.8
Industry
24.5
Forward
-19.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.9
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-6.4
Industry
23.4
More Details
21.3
P/B
P/B
Price to Book Value
21.3
vs History
6
vs Industry
11
Median 3Y
5.5
Median 5Y
4.8
Industry
3.1
More Details
30.8
EV/S
EV/S
Enterprise Value to Sales
30.8
vs History
6
vs Industry
42
Median 3Y
5.6
Median 5Y
6.5
Industry
8.2
Forward
24.7
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
37
Median 3Y
6.5
Median 5Y
8.3
Industry
9.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-4
Industry
6
Forward
-23.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-4
Industry
6.4
Forward
-17.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.6
Industry
7.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-4
Median 5Y
-4.4
Industry
5.7
More Details
19.1
EV/IC
EV/IC
Enterprise Value to IC
19.1
vs History
20
vs Industry
24
Median 3Y
6.2
Median 5Y
8.3
Industry
5.3
More Details

Multiples Across Competitors

Competitors Multiples
CStone Pharmaceuticals Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
CStone Pharmaceuticals
HKEX:2616
7.3B HKD 33.2 -17.8 -17.6 -17.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 321 758.3 -163 126.2 -198 087.3 -195 826.9
US
Abbvie Inc
NYSE:ABBV
392.1B USD 6.5 165.8 16.2 23
US
Amgen Inc
NASDAQ:AMGN
174.1B USD 4.9 25.1 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
148.4B USD 5.1 18.3 12.3 12.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 052.6 -523.8 -570.3 -555.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.9B USD 9.1 29.1 21.2 22.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
68.8B USD 4.8 15 14.1 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58.1B USD 23.7 -182.5 -455.3 -312.6
AU
CSL Ltd
ASX:CSL
86.2B AUD 3.6 18.8 12.7 15.8
NL
argenx SE
XBRU:ARGX
46B EUR 14.7 34.6 59.9 61.5
P/S Multiple
Revenue Growth P/S to Growth
CN
CStone Pharmaceuticals
HKEX:2616
Average P/S: 3 120 356.1
33.2
20%
1.7
FR
Pharnext SCA
OTC:PNEXF
34 321 758.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 052.6
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.1
10%
0.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.8
5%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.7
44%
0.5
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.7
46%
0.3
P/E Multiple
Earnings Growth PEG
CN
CStone Pharmaceuticals
HKEX:2616
Average P/E: 43.8
Negative Multiple: -17.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 126.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
8%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -182.5 N/A N/A
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
NL
argenx SE
XBRU:ARGX
34.6
37%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
CStone Pharmaceuticals
HKEX:2616
Average EV/EBITDA: 22.1
Negative Multiple: -17.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 087.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -570.3 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
16%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
9%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -455.3 N/A N/A
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
59.9
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
CStone Pharmaceuticals
HKEX:2616
Average EV/EBIT: 24.1
Negative Multiple: -17.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 826.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
19%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
13%
0.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -555.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
17%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
12%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -312.6 N/A N/A
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
61.5
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 295,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.